MedPharm || طبصيدلة

A 92-year-old man recently diagnosed with early stage prostate cancer is asymptomatic. His physician recommends observation. Which of the following is a rationale for recommending observation in this patient? A. Life expectancy of less than 10 years B. Early stage prostate cancer with long expected survival C. Avoids toxicity of unnecessary therapy D. Avoids cost of unnecessary therapy E. All of the above

Which of the following describes antiandrogen withdrawal? A. Discontinuing antiandrogen therapy in a patient with prostate cancer that has progressive disease on an antiandrogen B. Adding an additional antiandrogen in a patient progressing on an LHRH agonist C. A strategy to decrease the tumor flare associated with starting an LHRH agonist D. All of the above E. None of the above

Which of the following is true regarding finasteride and dutasteride in the prevention of prostate cancer? A. Dutasteride is FDA approved for prostate cancer chemoprevention. B. Finasteride is FDA approved for prostate cancer chemoprevention. C. Both finasteride and dutasteride are FDA approved for prostate cancer chemoprevention. D. Neither agent is FDA approved, but the benefits and risks should be discussed with men with a normal PSA result and undergoing regular screening. E. Neither agent is FDA approved and should not be used.

A 57 years old man with positive family history of prostate cancer. All of the following statements regarding screening and prevention of prostate cancer are true EXCEPT: a- Guidelines do not recommend the use of dutasteride for prostate cancer chemoprevention. b- Screening for prostate cancer is important and recommended c- Screening every 5 years may be adequate d- Males who elect to have screening should do so no more than every 2 years e- Guidelines do not recommend the use of finasteride for prostate cancer chemoprevention.